These Analysts Slash Their Forecasts On Zimmer Biomet Following Q1 Results

Benzinga04-29

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported upbeat earnings for the first quarter on Tuesday.

The company posted first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.

The orthopedic implant maker reported sales of $2.087 billion, up 9.3% on a reported basis, up 6.8% on a constant currency basis, and 2.9% on an organic constant currency basis, beating the consensus of $2.07 billion.

"We are off to a solid start to the year — strategically, operationally, and financially," said Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet.

Zimmer Biomet raised fiscal adjusted earnings guidance from $8.30-$8.45 per share to $8.40-$8.55 per share, compared to the consensus of $8.40.

The company reaffirms 2026 sales guidance of $8.44 billion-$8.60 billion versus the consensus of $8.56 billion.

Zimmer Biomet shares fell 2.6% to trade at $80.65 on Wednesday.

These analysts made changes to their price targets on Zimmer Biomet following earnings announcement.

Stifel analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $110 to $105.
Truist Securities analyst Richard Newitter reiterated the stock with a Hold and lowered the price target from $98 to $92.
Barclays analyst Matt Miksic maintained Zimmer Biomet with an Underweight rating and lowered the price target from $100 to $94.
Wells Fargo analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and cut the price target from $98 to $90.

Considering buying ZBH stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631887546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631887546","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On Zimmer Biomet Following Q1 Results","media":"Benzinga","content":"<html><body><p><strong>Zimmer Biomet Holdings, Inc</strong>. (NYSE:ZBH) reported upbeat earnings for the first quarter on Tuesday.</p>\n<p>The company posted first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.</p>\n<p>The orthopedic implant maker reported sales of $2.087 billion, up 9.3% on a reported basis, up 6.8% on a constant currency basis, and 2.9% on an organic constant currency basis, beating the consensus of $2.07 billion.</p>\n<p>\"We are off to a solid start to the year — strategically, operationally, and financially,\" said Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet.</p>\n<p>Zimmer Biomet raised fiscal adjusted earnings guidance from $8.30-$8.45 per share to $8.40-$8.55 per share, compared to the consensus of $8.40.</p>\n<p>The company reaffirms 2026 sales guidance of $8.44 billion-$8.60 billion versus the consensus of $8.56 billion.</p>\n<p>Zimmer Biomet shares fell 2.6% to trade at $80.65 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Zimmer Biomet following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/SFB\">Stifel</a> analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $110 to $105.</li>\n<li>Truist Securities analyst Richard Newitter reiterated the stock with a Hold and lowered the price target from $98 to $92.</li>\n<li>Barclays analyst Matt Miksic maintained Zimmer Biomet with an Underweight rating and lowered the price target from $100 to $94.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and cut the price target from $98 to $90.</li>\n</ul>\n<p><strong>Considering buying ZBH stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"470\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-1024x470.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-1024x470.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-300x138.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-768x352.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695.png 1216w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On Zimmer Biomet Following Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On Zimmer Biomet Following Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-04-29 23:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Zimmer Biomet Holdings, Inc</strong>. (NYSE:ZBH) reported upbeat earnings for the first quarter on Tuesday.</p>\n<p>The company posted first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.</p>\n<p>The orthopedic implant maker reported sales of $2.087 billion, up 9.3% on a reported basis, up 6.8% on a constant currency basis, and 2.9% on an organic constant currency basis, beating the consensus of $2.07 billion.</p>\n<p>\"We are off to a solid start to the year — strategically, operationally, and financially,\" said Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet.</p>\n<p>Zimmer Biomet raised fiscal adjusted earnings guidance from $8.30-$8.45 per share to $8.40-$8.55 per share, compared to the consensus of $8.40.</p>\n<p>The company reaffirms 2026 sales guidance of $8.44 billion-$8.60 billion versus the consensus of $8.56 billion.</p>\n<p>Zimmer Biomet shares fell 2.6% to trade at $80.65 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Zimmer Biomet following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/SFB\">Stifel</a> analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $110 to $105.</li>\n<li>Truist Securities analyst Richard Newitter reiterated the stock with a Hold and lowered the price target from $98 to $92.</li>\n<li>Barclays analyst Matt Miksic maintained Zimmer Biomet with an Underweight rating and lowered the price target from $100 to $94.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and cut the price target from $98 to $90.</li>\n</ul>\n<p><strong>Considering buying ZBH stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"470\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-1024x470.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-1024x470.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-300x138.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695-768x352.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/04/29110902/image-695.png 1216w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBH","symbol_name":"齐默巴奥米特控股","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/04/52134496/these-analysts-slash-their-forecasts-on-zimmer-biomet-following-q1-results","article_id":"2631887546","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631887546","pubTimestamp":1777475403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported strong Q1 earnings, beating estimates and raising guidance. Analysts maintain mixed views on stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBH":"齐默巴奥米特控股","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4566":"资本集团","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4588":"碎股","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4585":"ETF&股票定投概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"这些分析师在第一季度业绩公布后大幅下调了对Zimmer Biomet的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1.5},"content_text":"Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported upbeat earnings for the first quarter on Tuesday.\nThe company posted first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.\nThe orthopedic implant maker reported sales of $2.087 billion, up 9.3% on a reported basis, up 6.8% on a constant currency basis, and 2.9% on an organic constant currency basis, beating the consensus of $2.07 billion.\n\"We are off to a solid start to the year — strategically, operationally, and financially,\" said Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet.\nZimmer Biomet raised fiscal adjusted earnings guidance from $8.30-$8.45 per share to $8.40-$8.55 per share, compared to the consensus of $8.40.\nThe company reaffirms 2026 sales guidance of $8.44 billion-$8.60 billion versus the consensus of $8.56 billion.\nZimmer Biomet shares fell 2.6% to trade at $80.65 on Wednesday.\nThese analysts made changes to their price targets on Zimmer Biomet following earnings announcement.\n\nStifel analyst Rick Wise maintained Zimmer Biomet with a Buy and lowered the price target from $110 to $105.\nTruist Securities analyst Richard Newitter reiterated the stock with a Hold and lowered the price target from $98 to $92.\nBarclays analyst Matt Miksic maintained Zimmer Biomet with an Underweight rating and lowered the price target from $100 to $94.\nWells Fargo analyst Larry Biegelsen maintained the stock with an Equal-Weight rating and cut the price target from $98 to $90.\n\nConsidering buying ZBH stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631887546","isCrawlerRequest":true}